Navigation Links
Progressive in Biological Technology

Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders

... Test - the first test to determine the risk of progressive scoliosis - as well as expand the development of ... of time we were able to crack the genetic code to progressive scoliosis using our GenDB database," said John ... only test that utilizes the genetic blueprint of progressive scoliosis to enable physicians to identify which ...

BioMS Medical announces second quarter 2009 results

... evaluating dirucotide in patients with secondary progressive multiple sclerosis and with a positive outcome, ... of dirucotide for the treatment of secondary progressive MS (SPMS): - MAESTRO-01: This pivotal ... pivotal phase III clinical trials for Secondary progressive MS patients, MAESTRO-01 in Canada and Europe and ...

Shamir Optical Industry Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website

... of innovative products and technology to the progressive spectacle lens market. Utilizing its proprietary ... develops, designs, manufactures, and markets progressive lenses to sell to the ophthalmic market. In ... under service and royalty agreements. progressive lenses are used to treat presbyopia, a vision ...

BioMS Medical Announces First quarter 2009 results

... evaluating dirucotide in patients with secondary progressive multiple sclerosis, in the second half of 2009," ... potential for the treatment of secondary progressive multiple sclerosis." Currently, BioMS is ... of dirucotide for the treatment of secondary progressive MS (SPMS): - MAESTRO-01: On January ...

BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board

... trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and ... efficacy of dirucotide in patients with secondary progressive MS. The study is being conducted at 47 sites ... pivotal phase III clinical trials for Secondary progressive MS patients, MAESTRO-01 in Canada and Europe and ...

BioMS Medical Announces 2008 Year End Results

... of MS, specifically in patients with secondary progressive multiple sclerosis." Currently, BioMS is ... of dirucotide for the treatment of secondary progressive MS (SPMS): - MAESTRO-01: On ... pivotal phase III clinical trials for Secondary progressive MS patients, MAESTRO-01 in Canada and Europe and ...

BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis

... program for dirucotide is for secondary progressive MS where it is being evaluated in two ongoing ... outcomes in the ongoing phase III secondary progressive MS trials. The data also showed that dirucotide ... as a potential treatment for patients with progressive MS and we believe that these results are ...

BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA

... for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently ... become a first-in-class treatment for secondary progressive MS patients, a large patient population with very ... A pivotal phase II/III trial for secondary progressive MS (SPMS) patients in Canada and Europe. - ...

BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis

... (MBP8298) in patients with secondary progressive MS. The interim analysis included patients from ... A pivotal phase II/III trial for secondary progressive MS (SPMS) patients in Canada and Europe. - ... dirucotide (MBP8298) in patients with secondary progressive MS. The study is being conducted at 47 sites ...

BioMS Medical Announces Second Quarter 2008 Results

... that MAESTRO-03, our U.S. phase III secondary progressive MS trial, was fully recruited with approximately ... (dirucotide) for the treatment of secondary progressive MS (SPMS). The study has completed full ... pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe ...

BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial

... A pivotal phase II/III trial for secondary progressive MS (SPMS) patients in Canada and Europe. 2. ... percent of all MS patients have the secondary progressive form of the disease. About BioMS Medical Corp. ... pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe ...

Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline

... ) NASH is a form of progressive liver disease resulting from triglyceride fat ... beverages. About NASH NASH is a form of progressive liver disease characterized by the accumulation ... and show no outward signs of liver disease, the progressive nature of NASH can lead to cirrhosis and ...

Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend

... of innovative products and technology to the progressive ophthalmic lens market, announced today that its ... of innovative products and technology to the progressive spectacle lens market. Utilizing its ... under service and royalty agreements. progressive lenses are used to treat presbyopia, a vision ...

Lilly and BioMS Medical Announce Global Licensing and Development Agreement

... pivotal phase III clinical trials in secondary progressive MS (SPMS) and one phase II clinical trial ... potential in slowing the progression of secondary progressive MS, and thus may provide an effective therapeutic ... for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, ...

Shamir Optical Industry Ltd. Reports Third Quarter 2007 Results

... of innovative products and technology to the progressive ophthalmic lens market, today announced unaudited ... of innovative products and technology to the progressive spectacle lens market. Utilizing its ... under service and royalty agreements. progressive lenses are used to treat presbyopia, a vision ...

Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

... 2007. About Parkinson's Disease Parkinson's disease is a progressive movement disorder that affects a million people in the United States. Its ... controlling movement and coordination, so Parkinson's patients exhibit a progressive inability to initiate and control physical movements. There is currently ...

Novel drug discovery tool could identify promising new therapies for Parkinson's disease

... and coordination. As those neurons degenerate, the disease leads to progressive deterioration of motor function including involuntary shaking, slowed ... of the disease, and there is currently no means to slow the disease's progressive course. In most cases, the cause of Parkinson's disease is unknown, but ...

EyeIC Receives FDA 510(k) Clearance for MatchedFlicker(TM) Retinal Aid Detection Technology

... offers ophthalmologists a powerful new tool for the detection of progressive glaucoma," said Nathan Radcliffe, M.D., Director of Glaucoma at Weill ... historical optic nerve photos and plays a unique role in the detection of progressive glaucoma." EyeIC was founded in 2004 with a portfolio of intellectual ...

BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board

... phase III MAESTRO-03 trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue ... is being evaluated in two pivotal phase III clinical trials for Secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United ...

Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... stiffness and motion restriction in multiple joints. Because RA is a progressive disease, over time it can cause permanent joint deformity and severe ... Ankylosing Spondylitis Ankylosing spondylitis is a painful and progressive form of spinal arthritis, and symptoms of inflammatory back pain often ...

TeleHealth Services and Lakeland HealthCare Connect to Create Outstanding Patient Experience

... with Lakeland's vision of improving the hospital experience by being progressive and consumer responsive, the Michigan-based health system determined the ... education and improvements in health care. The combination of Lakeland's progressive initiatives and the latest in healthcare television and interactive ...

AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nation's Number One Killer

... motion simulator that helps people visualize atherosclerosis (athero), the progressive buildup of plaque inside the arteries. The Artery Explorer kicks off its ... Explorer in person. About Atherosclerosis (Athero) Athero is the progressive buildup of plaque -- made of fat, cholesterol, and other substances -- in ...

TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity

... of the aged population. Parkinson's Disease is the second most common progressive neurodegenerative disease after Alzheimer's Disease. About 1 million ... with Parkinson's Disease in the US. Symptoms progress from tremor to progressive loss of movement control and rigidity. In some instances the disease may ...

Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease

... other common therapies for Alzheimer's." Alzheimer's disease is a progressive and fatal neurological disease characterized by a substantial decrease in ... About Alzheimer's Disease AD, the most common form of dementia, is a progressive and fatal disease for which there is no cure. It attacks the brain's nerve ...

FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)

... bronchitis(4) -- which result in chronic airway inflammation(4) and progressive loss of lung function, making it difficult to breathe normally.(4,6) ... of breath, chronic cough, wheezing and excess mucus.(4) COPD is a progressive disease, which means people with COPD can expect lung function to worsen ...

HiveMind Marketing to Enhance Search Results for Chemistry Solutions Leader ChemBridge

... marketing activities measuring the results HiveMind Marketing's progressive lead generation methodologies, which increase critical pipeline capture, flow and conversion, are redefining the way progressive organizations select business-critical lead-generation resources. With ...

BioMS Medical recognized at Scrip Awards 2008

... on developing an effective therapeutic option for patients with secondary progressive MS, a debilitating disease of global proportion for which there are ... is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United ...

Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH

... of the American Society of Hematology. "The common, severe and progressive clinical consequences of PNH are becoming more apparent as researchers ... in patients with PNH." Pulmonary artery hypertension is a rare, progressive disorder characterized by high blood pressure (hypertension) of the ...

St. Paul Radiology Selects AMICAS

... One of the country's largest and most progressive radiology groups partners with AMICAS to enable productivity and growth ... about partnering with St. Paul Radiology, one of the largest and most progressive radiology groups in the country," said Stephen Kahane MD, president, chief ...

Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease

... trials. About Parkinson's Disease Parkinson's disease is a progressive movement disorder that affects a million people in the United States. Its ... controlling movement and coordination, so Parkinson's patients exhibit a progressive inability to initiate and control physical movements. There is currently ...

BioMS Medical Announces Third Quarter 2008 Results

... Europe evaluating dirucotide (MBP8298) for the treatment of secondary progressive MS (SPMS). The study has completed full recruitment of 611 patients ... is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United ...

BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board

... III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue ... is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United ...

BioMS Medical announces receipt of milestone payment from Eli Lilly and Company

... trial (MAESTRO-01) of dirucotide (MBP8298) in patients with secondary progressive MS. The independent Data Safety Monitoring Board (DSMB) for the MAESTRO-01 ... is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United ...

FDA Grants Epeius Biotechnologies' Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas

... in metastatic cancers of the colon, breast, skin, lung, and bone in a progressive program of expanded access that continues to achieve historic milestones. ... to the dedication and efforts of the many pioneering oncologists, the progressive medical institutions, and the conscientious regulatory agencies who have ...

ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer

... significant biological activity without toxicity in patients with progressive chemo-resistant pancreatic cancer. Once the overall safety record of ... of Rexin-G are safe and well-tolerated. The importance of these progressive dose-escalation studies -- which clearly establish safety before ...

BioMS Medical announces first quarter 2008 results

... evaluating dirucotide (MBP8298) for the treatment of secondary progressive MS (SPMS). On January 22, 2007, BioMS announced that the trial had ... is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United ...

Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial

... survival. ABOUT HUNTINGTON'S DISEASE Huntington's disease is a progressive neurodegenerative disease caused by a defective gene that is often ... responsible for controlling cognitive, emotional and motor functions. This progressive deterioration results in a variety of symptoms including uncontrolled ...

Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation

... and headache. About Alzheimer's Disease Alzheimer's disease is a progressive disease of the brain and the most common type of dementia. Dementia is used to describe the progressive loss of cognitive, intellectual, or functional abilities. Published ...

Remergent(R) Announces the Launch of Four New Products Pioneers of DNA Repair Expand Anti-Aging Line

... products to the Remergent line: Advanced Retinol Therapy (1% retinol), progressive Retinol Complex (0.4% retinol), Clarifying Concentrate2 and Complete ... wrinkles, age spots and uneven skin tone without irritation. -- progressive Retinol Complex -- is a skin perfecting treatment formulated with 0.4% ...

Historic Breakthrough in Fighting Children's Batten Disease as China Stem Cells Give New Lease on Life to 6 Year Old California Boy

... or NCLs. Due to a genetic defect at birth, over time those with NCL suffer progressive nervous system breakdown leading to mental impairment, worsening seizures, ... are loss of muscle coordination known as ataxia and seizures, along with progressive mental deterioration. Blake has suffered all these symptoms in the past ...
Other Contents
(Date:10/14/2014)... ATHENS, Ohio (Oct. 14, 2014)—It,s been millions of years ... but a team led by Ohio University scientists is ... to model airflow through dinosaur snouts. The research has ... not only breathe but to enhance the sense of ... pretty ,nosy, animals," said Ohio University doctoral student Jason ...
(Date:10/14/2014)... 14, 2014 – High doses of fish oil supplements, rich ... common type of irregular heartbeat in which the heart can ... of the AFFORD trial led by the Montreal Heart Institute ... of Cardiology on October 7th. , For the trial, ... were randomly assigned to 4 grams of fish oil a ...
(Date:10/14/2014)... likely takes between 10 and 20 years to ... window" of intervention if detected early, which may ... say Australian clinical researchers. , Dr Jeremy ... Institute of Medical Research, analysed medical histories and ... pancreatic cancer patients, operated on between 1994 and ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Early detection window when pancreatic cancer is in the family 2
(Date:10/20/2014)... (PRWEB) October 20, 2014 Succeed is proud ... local companies who participated in the Every Body Walk! ... a public awareness project that encourages workers to be more ... Step 10,000 Program, which concluded at the end of September, ... of cities and metro areas. Participating companies gave their ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 National Teen ... Chapter of the American Academy of Pediatrics (Ohio AAP, ... (NHTSA) in encouraging parents of teen drivers to talk to ... the road. , Motor vehicle crashes are the leading cause ... teen drivers involved in fatal crashes, and 859 (42%) of ...
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... Punzoné , the first line of ultra-premium ... lot to celebrate this month. October marks Italian Heritage Month ... contributions of Americans of Italian heritage and Italians in America. ... shares its favorite Italian cocktails and encourages everyone to enjoy ... if it is only in a glass. , Punzoné ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
Other TagsOther Tags